Cite
HARVARD Citation
Inoa, J. et al. (n.d.). 2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era. International journal of gynecological cancer. p. A306. [Online].